TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11395986
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation (FeSO4) for 18 weeks
Study: 9257425
Drug: Sargramostim (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sargramostim (300 micrograms; 193 mg/m2)
Study: 9257425
Drug: Filgrastim (481
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (481 mg; 7 mg/kg)
Study: 3037835
Drug: High-dose ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ketoconazole (400 mg every 8 h)
Study: 3037835
Drug: High-dose ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ketoconazole (400 mg every 8 h) + Dexamethasone (0.5 mg twice daily)
Study: 29615172
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with adjunctive mitomycin C
Study: 19025306
Drug: Somatostatin (SOM,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (SOM, 250 mg)
Study: 19025306
Drug: Octreotide (OCT,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (OCT, 50 mg)
Study: 20087643
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine and behavioral counseling
Study: 12091996
Drug: Filgrastim treatment
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim treatment
Study: 12091996
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment (without filgrastim)
Study: 9494305
Drug: Dextropropoxyphene (DPP)
Normalized name: dextropropoxyphene
DrugBank: Dextropropoxyphene (DB00647)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextropropoxyphene (DPP) 120 mg to 240 mg daily
Study: 9494305
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine 20 mg daily
Study: 3141290
Drug: bacampillin 800
Normalized name: bacampicillin 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bacampillin 800 mg b.i.d. for ten days
Study: 3141290
Drug: amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin 500 mg t.i.d. for ten days
Study: 3141290
Drug: amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin 500 mg t.i.d.
Study: 3141290
Drug: bacampillin 800
Normalized name: bacampicillin 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bacampillin 800 mg b.i.d.
Study: 30106834
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Cytology, FISH, and MP
Study: 30106834
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FISH and MP
Study: 30128092
Drug: Persian Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persian Medicine Protocol (intranasal lavender oil, Liquorice Marjoram Tea)
Study: 30128092
Drug: Classical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical treatment (systemic and intranasal cortisone)
Study: 30128092
Drug: Persian Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persian Medicine Protocol
Study: 17261560
Drug: Physiotherapy (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy (10 treatments: deep‐friction, pulsed ultrasound, ice, sensory motor training)
Study: 9543905
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education intervention (one-on-one education session by a nephrology nurse using a teaching booklet, Osteodystrophy Tool, and medication diary)
Study: 7509380
Drug: Taxol (paclitaxel)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Taxol (paclitaxel) 250 mg/m2 without G-CSF
Study: 7509380
Drug: Taxol (paclitaxel)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Taxol (paclitaxel) 300 mg/m2 with G-CSF
Study: 7509380
Drug: Taxol (paclitaxel)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Taxol (paclitaxel) 250 mg/m2
Study: 3132962
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment with intracoronary streptokinase
Study: 18450124
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 2000 microg nebulized budesonide
Study: 18450124
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of 4 x 500 microg nebulized budesonide
Study: 17162433
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anticoagulant)
Study: 10426453
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 plus doxorubicin 50 mg/m2
Study: 10426453
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m2 plus doxorubicin 60 mg/m2
Study: 8848891
Drug: mivacurium (final
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium (final dose 70 micrograms kg‐1)
Study: 354329
Drug: Fluphenazine enanthate
Normalized name: Fluphenazine Enanthate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine enanthate (high doses, 10-20 times higher than normal)
Study: 354329
Drug: Fluphenazine enanthate
Normalized name: Fluphenazine Enanthate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine enanthate (high doses)
Study: 28636188
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued on pressure lowering medication)
Study: 22101760
Drug: Tocilizumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (4 or 8 mg/kg intravenous infusions every 4 weeks for a total of 6 doses)
Study: 8345382
Drug: Surfactant administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant administration by pump
Study: 8345382
Drug: Surfactant administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant administration by hand-dosing method
Study: 24327590
Drug: Pharmacist intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist intervention (medication reconciliation and patient education)
Study: 18356697
Drug: Nicorandil therapy
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil therapy (15 mg/day; n = 26)
Study: 9735589
Drug: Nonrandom assignment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonrandom assignment (self-selected treatment)
Study: 20081798
Drug: Cavinton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavinton therapy
Study: 15564311
Drug: hylan G-F
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: hylan G-F 20
Study: 9893736
Drug: Oral L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine (7 g twice daily)
Study: 8281847
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg four times a day
Study: 8281847
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg four times a day
Study: 2525337
Drug: danazol, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: danazol, 800 mg/day (n = 10)
Study: 2525337
Drug: danazol, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: danazol, 600 mg/day (n = 8)
Study: 2525337
Drug: intranasal nafarelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal nafarelin acetate, 800 micrograms/day (n = 10)
Study: 2525337
Drug: intranasal nafarelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal nafarelin acetate, 400 micrograms/day (n = 25)
Study: 25807927
Drug: Hydromorphone immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone immediate-release (IR) tablets
Study: 25807927
Drug: Hydromorphone extended-release
Normalized name: hydromorphone Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone extended-release (ER) tablets
Study: 25807927
Drug: Hydromorphone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone IR and ER tablets (fed condition)
Study: 25807927
Drug: Hydromorphone tablets
Normalized name: hydromorphone Oral Tablet
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone tablets (both IR and ER)
Study: 24048387
Drug: Citalopram 40
Normalized name: citalopram 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 40 mg/day plus quetiapine 300 to 600 mg/day
Study: 24048387
Drug: Citalopram 40
Normalized name: citalopram 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 40 mg/day plus placebo
Study: 21822077
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg/kg) and Hydroxyzine (1 mg/kg)
Study: 17896496
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Parol and written notice about the content of root canal treatment
Study: 15472200
Drug: Atorvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin treatment for 16 weeks
Study: 7993812
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow transplantation (ABMT) with involved marrow infusion
Study: 2917115
Drug: extradural 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: extradural 0.5% bupivacaine hydrochloride 0.75 mg kg‐1
Study: 2917115
Drug: extradural 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: extradural 0.1% methadone hydrochloride 4 mg after bupivacaine
Study: 2917115
Drug: continuous extradural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous extradural infusion of methadone 0.3 mg h‐1 after operation
Study: 4584150
Drug: THC 3
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 3 μg/kg
Study: 4584150
Drug: THC 6
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 6 μg/kg
Study: 4584150
Drug: THC 9
Normalized name: delta-9-THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 9 μg/kg
Study: 4584150
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 μg/kg THC)
Study: 4584150
Drug: THC doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC doses (3, 6, 9 μg/kg)
Study: 15821181
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2 g/d)
Study: 15009708
Drug: Ultraviolet-radiation (UVR)
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultraviolet-radiation (UVR) exposure at 1 minimal erythema dose (MED)
Study: 3526790
Drug: Physostigmine salicylate
Normalized name: PHYSOSTIGMINE SALICYLATE
DrugBank: Physostigmine (DB00981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine salicylate 2 mg
Study: 3526790
Drug: Pethidine chloride
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine chloride 50 mg
Study: 29935544
Drug: Baicalin 500
Normalized name: BAICALIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baicalin 500 mg orally every day for 12 weeks
Study: 2540392
Drug: Combination (C)
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (C)
Study: 9685512
Drug: Alendronate 5
Normalized name: ALENDRONATE 5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 5 mg/day
Study: 7041039
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E treatment
Study: 7600430
Drug: No vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No vitamin E treatment
Study: 1292438
Drug: Psychiatric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric treatment (PT)
Study: 9199724
Drug: Multimodal behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal behavioural therapy (MBT)
Study: 6442711
Drug: Auranofin 6
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin 6 mg daily and placebo injection
Study: 6442711
Drug: Sodium aurothiomalate
Normalized name: Sodium aurothiomalate
DrugBank: Sodium aurothiomalate (DB09276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium aurothiomalate 50 mg monthly and placebo tablets
Study: 6442711
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Auranofin and Sodium aurothiomalate)
Study: 29848769
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin or warfarin
Study: 27695980
Drug: Mental fatigue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental fatigue plus caffeine ingestion (5 mg/kg) (MF-CAF)
Study: 25894953
Drug: Adjunctive edivoxetine
Normalized name: Edivoxetine
DrugBank: Edivoxetine (DB09184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive edivoxetine (12-18 mg/day)
Study: 24995890
Drug: Adjunctive edivoxetine
Normalized name: Edivoxetine
DrugBank: Edivoxetine (DB09184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive edivoxetine
Study: 18796622
Drug: DPP intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP intervention groups (placebo, lifestyle, metformin)
Study: 16816561
Drug: Antibiotics (metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (metronidazole plus erythromycin antenatally and metronidazole plus ampicillin intrapartum)
Study: 2523645
Drug: Isradipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5 mg or 5 mg twice daily)
Study: 356497
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg) and Triamterene (50 mg) with possible addition of Methyldopa (up to 2 g daily)
Study: 31848551
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (40 g daily)
Study: 31848551
Drug: Casein protein
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein protein (40 g daily)
Study: 28711736
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose psilocybin (0.160 mg/kg)
Study: 28711736
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose psilocybin (0.215 mg/kg)
Study: 28711736
Drug: Psilocybin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (both doses)
Study: 23596237
Drug: Antituberculosis agents
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antituberculosis agents
Study: 18310963
Drug: Interferon-beta (dose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta (dose: 6 MU, daily for 4, 6, or 8 weeks)
Study: 14680546
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg/day (n = 7)
Study: 14680546
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 100 mg/day (n = 8)
Study: 11110233
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily
Study: 11110233
Drug: Calcipotriene 0.005%
Normalized name: CALCIPOTRIENE 0.005% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene 0.005% ointment twice daily
Study: 8642525
Drug: 5% hypertonic
Normalized name: Walgreens Sodium Chloride 5% Hypertonicity Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% hypertonic saline solution
Study: 8366876
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg saperconazole per day for 7 days
Study: 8366876
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg saperconazole per day for 7 days
Study: 8366876
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg saperconazole per day for 14 days
Study: 2889281
Drug: 6-month regimen
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month regimen of daily isoniazid plus rifampicin, supplemented by streptomycin twice a week for the first 6 months
Study: 2889281
Drug: 9-month regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-month regimen of daily isoniazid plus rifampicin, supplemented by streptomycin twice a week for the first 6 months
Study: 28729014
Drug: Oral phenazopyridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral phenazopyridine
Study: 22525443
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplementation (MMS) given at twice the recommended dietary allowance (RDA)
Study: 22525443
Drug: Six-multivitamin (MV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-multivitamin (MV) supplement given in one RDA as the 'standard of care'
Study: 22525443
Drug: Six-multivitamin (MV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-multivitamin (MV) supplement
Study: 21243936
Drug: Sublingual peach
Normalized name: Peach
DrugBank: Peach (DB10552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual peach immunotherapy (standardized peach extract quantified in mass units of Pru p 3) for 6 months
Study: 8934061
Drug: Nomegestrol subdermal
Normalized name: nomegestrol
DrugBank: Nomegestrol acetate (DB13981)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Nomegestrol subdermal contraceptive implant (Uniplant)
Study: 1877516
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (discontinuation)
Study: 26493304
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg with morphine 5 mg
Study: 26493304
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg with placebo
Study: 24906437
Drug: Tapentadol ER
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol ER (50-250 mg twice daily)
Study: 24906437
Drug: Morphine SR
Normalized name: Ratio-Morphine SR
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine SR (20-140 mg/day)
Study: 22854406
Drug: Pure ß-carotene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure ß-carotene in oil (0.5 mg)
Study: 22854406
Drug: Golden Rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golden Rice ß-carotene (0.6 mg)
Study: 22854406
Drug: Spinach ß-carotene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinach ß-carotene (1.4 mg)
Study: 19736632
Drug: CO2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CO2 treatment for 18 consecutive days
Study: 11806476
Drug: Braun Oral-B
Normalized name: bran Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral-B D17 power toothbrush
Study: 9488498
Drug: Histamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine infusion (0.16 microg/kg/min) after 30 minutes of pretreatment with low L-NMMA
Study: 9488498
Drug: Histamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine infusion (0.16 microg/kg/min) after 30 minutes of pretreatment with high L-NMMA
Study: 9488498
Drug: Histamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine infusion alone (no L-NMMA pretreatment)
Study: 3386328
Drug: Flunitrazepam (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (three intravenous dose levels)
Study: 9075669
Drug: Spironolactone 225
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 225 mg/day
Study: 8416267
Drug: Low-dose isotretinoin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose isotretinoin (0.5 mg per kilogram per day)
Study: 8416267
Drug: Beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta carotene (30 mg per day)
Study: 30796508
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg phytosomal curcumin (Curserin®: 200 mg curcumin, 120 mg phosphatidylserine, 480 mg phosphatidylcholine and 8 mg piperine from Piper nigrum L. dry extract) for 8 weeks
Study: 30796508
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg phytosomal curcumin (Curserin®)
Study: 29406428
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) for 24 weeks
Study: 29406428
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (IPT) and antiretroviral therapy (ART)
Study: 26523653
Drug: Telmisartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (160 mg daily for 3 weeks)
Study: 20142024
Drug: Baseline NT-proBNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline NT-proBNP levels measured in pg/mL using the Elecsys proBNP assay (Roche)
Study: 15659491
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg oral gefitinib daily continuously
Study: 15659491
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral gefitinib daily continuously
Study: 12516646
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading of machined-surface Brånemark implants in healed bone
Study: 12516646
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading of machined-surface Brånemark implants in fresh extraction sites